Complications with the use of bone morphogenetic protein 2 (BMP-2) in spine surgery

Spine Journal

Volumn 14, Issue 3, 2014, Pages 552-559

  Tannoury, Chadi A ^a   An, Howard S ^b  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone morphogenetic protein; Complications; Ectopic bone; Fusion; Osteolysis; Radiculitis; Retrograde ejaculation; rhBMP 2; Spine

Indexed keywords

CALCIUM PHOSPHATE; COLLAGEN TYPE 1; DRUG CARRIER; POLYGLYCOLIC ACID; POLYLACTIC ACID; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 2; RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN-2; RECOMBINANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIBODY PRODUCTION; BONE DISEASE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CERVICAL SPINE; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; DYSPNEA; ECTOPIC BONE FORMATION; EDEMA; GRAFT FAILURE; HEMATOMA; HUMAN; INTERBODY GRAFT LUCENCY; INTERVERTEBRAL DISKECTOMY; LUMBAR SPINE; MOUTH CARCINOMA; NECK SWELLING; NERVE ROOT COMPRESSION; NERVE ROOT INJURY; NEUROLOGICAL COMPLICATION; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; PANCREAS CANCER; PRIORITY JOURNAL; RADICULITIS; RESPIRATORY TRACT DISEASE; RETROGRADE EJACULATION; REVIEW; SEROMA; SPINAL CORD TUMOR; SPINE FUSION; SPINE SURGERY; STOMACH CANCER; SWELLING; TREATMENT OUTCOME; URINE RETENTION; VERTEBRAL EDEMA; VERTEBRAL OSTEOLYSIS; WOUND COMPLICATION; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; LUMBAR VERTEBRA; OSSIFICATION, HETEROTOPIC; PROCEDURES; RADICULOPATHY; RISK FACTOR; SURGERY;

BONE MORPHOGENETIC PROTEIN 2; CERVICAL VERTEBRAE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOMA; HUMANS; LUMBAR VERTEBRAE; OSSIFICATION, HETEROTOPIC; RADICULOPATHY; RECOMBINANT PROTEINS; RISK FACTORS; SPINAL FUSION; TRANSFORMING GROWTH FACTOR BETA;

EID: 84896701922     PISSN: 15299430     EISSN: 18781632     Source Type: Journal    
DOI: 10.1016/j.spinee.2013.08.060     Document Type: Article

References (70)

1. M.R. Urist Bone: formation by autoinduction. 1965 Clin Orthop Relat Res 2002 4 10
2. E.A. Wang, V. Rosen, and P. Cordes et al. Purification and characterization of other distinct bone-inducing factors Proc Natl Acad Sci U S A 85 1988 9484 9488
3. H. Cheng, W. Jiang, and F.M. Phillips et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs) J Bone Joint Surg Am 85-A 2003 1544 1552
4. J.K. Burkus, M.F. Gornet, C.A. Dickman, and T.A. Zdeblick Anterior lumbar interbody fusion using rhBMP-2 with tapered interbody cages J Spinal Disord Tech 15 2002 337 349
5. J.K. Burkus, E.E. Transfeldt, and S.H. Kitchel et al. Clinical and radiographic outcomes of anterior lumbar interbody fusion using recombinant human bone morphogenetic protein-2 Spine 27 2002 2396 2408
6. J.K. Burkus, H.S. Sandhu, and M.F. Gornet Influence of rhBMP-2 on the healing patterns associated with allograft interbody constructs in comparison with autograft Spine 31 2006 775 781
7. P.V. Mummaneni, J. Pan, R.W. Haid, and G.E. Rodts Contribution of recombinant human bone morphogenetic protein-2 to the rapid creation of interbody fusion when used in transforaminal lumbar interbody fusion: a preliminary report. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004 J Neurosurg Spine 1 2004 19 23
8. A.T. Villavicencio, S. Burneikiene, and E.L. Nelson et al. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2 J Neurosurg Spine 3 2005 436 443
9. J.D. Schwender, L.T. Holly, D.P. Rouben, and K.T. Foley Minimally invasive transforaminal lumbar interbody fusion (TLIF): technical feasibility and initial results J Spinal Disord Tech 18 Suppl 2005 S1 S6
10. S.D. Glassman, L. Carreon, and M. Djurasovic et al. Posterolateral lumbar spine fusion with INFUSE bone graft Spine J 7 2007 44 49
11. C. Papakostidis, G. Kontakis, M. Bhandari, and P.V. Giannoudis Efficacy of autologous iliac crest bone graft and bone morphogenetic proteins for posterolateral fusion of lumbar spine: a meta-analysis of the results Spine 33 2008 E680 E692
12. S.D. Glassman, J.R. Dimar 3rd, and K. Burkus et al. The efficacy of rhBMP-2 for posterolateral lumbar fusion in smokers Spine 32 2007 1693 1698
13. H.J. Meisel, M. Schnoring, and C. Hohaus et al. Posterior lumbar interbody fusion using rhBMP-2 Eur Spine J 17 2008 1735 1744
14. D.S. Mulconrey, K.H. Bridwell, and J. Flynn et al. Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion Spine 33 2008 2153 2159
15. R. Fu, S. Selph, and M. McDonagh et al. Effectiveness and harms of recombinant human bone morphogenetic protein-2 in spine fusion: a systematic review and meta-analysis Ann Intern Med 158 2013 890 902
16. M.C. Simmonds, J.V. Brown, and M.K. Heirs et al. Safety and effectiveness of recombinant human bone morphogenetic protein-2 for spinal fusion: a meta-analysis of individual-participant data Ann Intern Med 158 2013 877 889
17. K.S. Cahill, J.H. Chi, A. Day, and E.B. Claus Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures JAMA 302 2009 58 66
18. S.J. Ackerman, M.S. Mafilios, and D.W. Polly Jr. Economic evaluation of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion: an evidence-based modeling approach Spine 27 16 Suppl 1 2002 S94 S99
19. S.D. Glassman, L.Y. Carreon, and M.J. Campbell et al. The perioperative cost of infuse bone graft in posterolateral lumbar spine fusion Spine J 8 2008 443 448
20. United States Food and Drug Administration, Department of Health and human services, Center for devices and Radiological Health. INFUSE bone graft/LT-cage? Lumbar tapered fusion devices - P000058. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm? num5P000058. 2002.
21. S.D. Boden, J. Kang, H. Sandhu, and J.G. Heller Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies Spine 27 2002 2662 2673
22. A.R. Vaccaro, J.P. Lawrence, and T. Patel et al. The safety and efficacy of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal study Spine 33 2008 2850 2862
23. S.A. Mindea, P. Shih, and J.K. Song Recombinant human bone morphogenetic protein-2-induced radiculitis in elective minimally invasive transforaminal lumbar interbody fusions: a series review Spine 34 2009 1480 1484 discussion 1485
24. J.A. Rihn, R. Patel, and J. Makda et al. Complications associated with single-level transforaminal lumbar interbody fusion Spine J 9 2009 623 629
25. R.D. Muchow, W.K. Hsu, and P.A. Anderson Histopathologic inflammatory response induced by recombinant bone morphogenetic protein-2 causing radiculopathy after transforaminal lumbar interbody fusion Spine J 10 2010 e1 e6
26. K. Owens, S.D. Glassman, and J.M. Howard et al. Perioperative complications with rhBMP-2 in transforaminal lumbar interbody fusion Eur Spine J 20 2011 612 617
27. V. Joseph, and Y.R. Rampersaud Heterotopic bone formation with the use of rhBMP2 in posterior minimal access interbody fusion: a CT analysis Spine 32 2007 2885 2890
28. R.J. Mannion, A.M. Nowitzke, and M.J. Wood Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2 - but what is the cost? Spine J 11 2011 527 533
29. D.A. Wong, A. Kumar, and S. Jatana et al. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2) Spine J 8 2008 1011 1018
30. J.W. McClellan, D.S. Mulconrey, R.J. Forbes, and N. Fullmer Vertebral bone resorption after transforaminal lumbar interbody fusion with bone morphogenetic protein (rhBMP-2) J Spinal Disord Tech 19 2006 483 486
31. K.U. Lewandrowski, C. Nanson, and R. Calderon Vertebral osteolysis after posterior interbody lumbar fusion with recombinant human bone morphogenetic protein 2: a report of five cases Spine J 7 2007 609 614
32. T.E. Mroz, J.C. Wang, R. Hashimoto, and D.C. Norvell Complications related to osteobiologics use in spine surgery: a systematic review Spine 35 9 Suppl 2010 S86 S104
33. E.J. Carragee, K.A. Mitsunaga, E.L. Hurwitz, and G.J. Scuderi Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study Spine J 11 2011 511 516
34. G.C. Comer, M.W. Smith, and E.L. Hurwitz et al. Retrograde ejaculation after anterior lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a 10-year cohort controlled study Spine J 12 2012 881 890
35. E.M. Lindley, Z.L. McBeth, and S.E. Henry et al. Retrograde ejaculation following anterior lumbar spine surgery Spine 2012
36. G. Tepper, R. Rabbani, M. Yousefzadeh, and D. Prince Quantitative assessment of retrograde ejaculation using semen analysis, comparison with a standardized qualitative questionnaire, and investigating the impact of rhBMP-2 Spine 38 2013 841 845
37. J.D. Smucker, J.M. Rhee, and K. Singh et al. Increased swelling complications associated with off-label usage of rhBMP-2 in the anterior cervical spine Spine 31 2006 2813 2819
38. FDA Public Health Notification. Life-threatening complications associated with recombinant human bone morphogenetic protein in cervical spine fusion. July 1, 2008. FDA.
39. G.R. Buttermann Prospective nonrandomized comparison of an allograft with bone morphogenic protein versus an iliac-crest autograft in anterior cervical discectomy and fusion Spine J 8 2008 426 435
40. L.M. Tumialan, J. Pan, G.E. Rodts, and P.V. Mummaneni The safety and efficacy of anterior cervical discectomy and fusion with polyetheretherketone spacer and recombinant human bone morphogenetic protein-2: a review of 200 patients J Neurosurg Spine 8 2008 529 535
41. L.B. Shields, G.H. Raque, and S.D. Glassman et al. Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion Spine 31 2006 542 547
42. R. Vaidya, R. Weir, and A. Sethi et al. Interbody fusion with allograft and rhBMP-2 leads to consistent fusion but early subsidence J Bone Joint Surg Br 89 2007 342 345
43. R. Vaidya, J. Carp, and A. Sethi et al. Complications of anterior cervical discectomy and fusion using recombinant human bone morphogenetic protein-2 Eur Spine J 16 2007 1257 1265
44. R. Vaidya, A. Sethi, and S. Bartol et al. Complications in the use of rhBMP-2 in PEEK cages for interbody spinal fusions J Spinal Disord Tech 21 2008 557 562
45. C.H. Crawford 3rd, L.Y. Carreon, and M.D. McGinnis et al. Perioperative complications of recombinant human bone morphogenetic protein-2 on an absorbable collagen sponge versus iliac crest bone graft for posterior cervical arthrodesis Spine 34 2009 1390 1394
46. J.C. Furlan, R.G. Perrin, and P.V. Govender et al. Use of osteogenic protein-1 in patients at high risk for spinal pseudarthrosis: a prospective cohort study assessing safety, health-related quality of life, and radiographic fusion. Invited submission from the Joint Section on Disorders of the Spine and Peripheral Nerves, March 2007 J Neurosurg Spine 7 2007 486 495
47. D.W. Anderson, D.C. Burton, and R.S. Jackson Postoperative cervical myelopathy and cord compression associated with the use of recombinant bone morphogenetic protein-2 in posterior cervical decompression, instrumentation, and arthrodesis: a report of two cases Spine 36 2011 E682 E686
48. J.N. Zara, R.K. Siu, and X. Zhang et al. High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo Tissue Eng Part A 17 2011 1389 1399
49. TM rhBMP-2 matrix: Orthopaedic and Rehabilitation Devices Advisory Panel Presentation. July 27, 2010. FDA.
50. S.D. Glassman, J.R. Dimar, and L.Y. Carreon et al. Initial fusion rates with recombinant human bone morphogenetic protein-2/compression resistant matrix and a hydroxyapatite and tricalcium phosphate/collagen carrier in posterolateral spinal fusion Spine 30 2005 1694 1698
51. J. Kleeff, H. Maruyama, and T. Ishiwata et al. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo Gastroenterology 116 1999 1202 1216
52. M. Laitinen, L. Jortikka, and T. Halttunen et al. Measurement of total and local bone morphogenetic protein concentration in bone tumours Int Orthop 21 1997 188 193
53. H. Yoshikawa, W.J. Rettig, and J.M. Lane et al. Immunohistochemical detection of bone morphogenetic proteins in bone and soft-tissue sarcomas Cancer 74 1994 842 847
54. H. Soda, E. Raymond, and S. Sharma et al. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units Anticancer Drugs 9 1998 327 331
55. A.R. Poynton, and J.M. Lane Safety profile for the clinical use of bone morphogenetic proteins in the spine Spine 27 16 Suppl 1 2002 S40 S48
56. D. Mines, Y. Gu, T.D. Kou, and G.S. Cooper Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study Pharmacoepidemiol Drug Saf 20 2011 111 118
57. J. Zhang, Y. Ge, and L. Sun et al. Effect of bone morphogenetic protein-2 on proliferation and apoptosis of gastric cancer cells Int J Med Sci 9 2012 184 192
58. H. Jin, J. Pi, and X. Huang et al. BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation Appl Microbiol Biotechnol 93 2012 1715 1723
59. D. Wang, P. Huang, and B. Zhu et al. Induction of estrogen receptor alpha-36 expression by bone morphogenetic protein 2 in breast cancer cell lines Mol Med Report 6 2012 591 596
60. N.A. Kokorina, J.S. Lewis Jr., and S.O. Zakharkin et al. rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo Laryngoscope 122 2012 95 102
61. J.P. Thawani, A.C. Wang, and K.D. Than et al. Bone morphogenetic proteins and cancer: review of the literature Neurosurgery 66 2010 233 246 discussion 246
62. S.M. Koehler, J.C. Latridis, and A. Hecht et al. Does BMP-2 really cause cancer? A systematic review of the literature - NASS meeting 2012 Spine J 12 2012 S143 S144
63. ® for anterior lumbar interbody fusion in patients with degenerative disc disease [Clinical Trial]. Available at: http://clinicaltrials.gov/ct2/results?term=NCT01491386&Search= Search. Accessed April 29, 2013.
64. M.F. Gornet, J.K. Burkus, R.F. Dryer, and J.H. Peloza Lumbar disc arthroplasty with Maverick disc versus stand-alone interbody fusion: a prospective, randomized, controlled, multicenter investigational device exemption trial Spine 36 2011 E1600 E1611
65. H.S. Sandhu Bone morphogenetic proteins and spinal surgery Spine 28 15 Suppl 2003 S64 S73
66. S.D. Boden, G.J. Martin Jr., and M. Morone et al. The use of coralline hydroxyapatite with bone marrow, autogenous bone graft, or osteoinductive bone protein extract for posterolateral lumbar spine fusion Spine 24 1999 320 327
67. S.N. Khan, J.F. Fraser, and H.S. Sandhu et al. Use of osteopromotive growth factors, demineralized bone matrix, and ceramics to enhance spinal fusion J Am Acad Orthop Surg 13 2005 129 137
68. A. Minamide, M. Kawakami, and H. Hashizume et al. Evaluation of carriers of bone morphogenetic protein for spinal fusion Spine 26 2001 933 939
69. D.Y. Suh, S.D. Boden, and J. Louis-Ugbo et al. Delivery of recombinant human bone morphogenetic protein-2 using a compression-resistant matrix in posterolateral spine fusion in the rabbit and in the non-human primate Spine 27 2002 353 360
70. C. Kraiwattanapong, S.D. Boden, and J. Louis-Ugbo et al. Comparison of Healos/bone marrow to INFUSE (rhBMP-2/ACS) with a collagen-ceramic sponge bulking agent as graft substitutes for lumbar spine fusion Spine 30 2005 1001 1007 discussion 1007